Chronic administration of octreotide ameliorates portal hypertension and portal hypertensive gastropathy in rats with cirrhosis

Clinical Science

Volumn 94, Issue 4, 1998, Pages 367-371

  Chan, Che Chang ^a   Lee, Fa Yauh ^a   Wang, Sun Sang ^a   Chang, Full Young ^a   Lin, Han Chieh ^a   Lin, Hwai Jeng ^a   Chu, Chi Jen ^a   Wu, Shwu Ling ^a   Tai, Chun Ching ^a   Lee, Shou Dong ^a  

^a NONE

Author keywords

Cirrhosis; Octreotide; Portal hypertension; Portal hypertensive gastropathy

Indexed keywords

CARBON TETRACHLORIDE; OCTREOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; HEMODYNAMICS; LIVER CIRRHOSIS; MALE; MORPHOMETRICS; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; STOMACH DISEASE; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTEMIC VASCULAR RESISTANCE;

EID: 0031966745     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0940367     Document Type: Article

References (49)

1. McCormack TT, Sims J, Eyre-Brook I, et al. Gastric lesions in portal hypertension: inflammatory gastritis or congestive gastropathy? Gut 1985; 26: 1226-32.
2. Papazian A, Braillon A, Dupas JL, Sevenet F, Capron JP. Portal hypertensive gastric mucosa: an endoscopic study. Gut 1986; 27: 1199-203.
3. Quintero E, Piqué JM, Bombi JA, et al. Gastric mucosal vascular ectasia causing bleeding in cirrhosis: a distinct entity associated with hypergastrinemia and low serum levels of pepsinogen I. Gastroenterology 1987; 93: 1054-61
4. Sarfeh IJ, Tarnawski A. Gastric mucosal vasculopathy in portal hypertension. Gastroenterology 1987; 93: 1129-31.
5. Sarfeh IJ, Tarnawski A, Malki A, Mason GR, Mach T, Ivey KJ. Portal hypertension and gastric mucosal injury in rats. Gastroenterology 1983; 84: 987-93
6. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983; 244: G52-7.
7. Piqué JM, Leung F, Kitahora T, Sarfeh IJ, Tarnawski A, Guth PH. Gastric mucosal blood flow and acid secretion in portal hypertensive rats. Gastroenterology 1988; 95: 727-33.
8. Iwao T, Toyonaga A, Ikegami M, et al. Reduced gastric mucosal blood flow in patients with portal-hypertensive gastropathy. Hepatology 1993; 18: 36-40.
9. Panés J, Bordas JM, Piqué JM, et al. Increased gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Gastroenterology 1992; 103: 1875-82.
10. Groszmann RJ, Vorobioff J, Riley E. Measurement of splanchnic haemodynamics in portal-hypertensive rats: application of labeled microsphere. Am J Physiol 1982; 242: G156-60.
11. Piqué JM, Pizcueta MP, Perez RM, Bosch J. Effects of propranolol on gastric mucosal blood flow and acid secretion in portal hypertensive rats. Hepatology 1990; 12: 476-80.
12. Lee FY, Wang SS, Tsai YT, et al. Aminoguanidine corrects hyperdynamic circulation without ameliorating portal hypertension and portal hypertensive gastropathy in anesthetized portal hypertensive rats. J Hepatol 1997; 26: 687-93.
13. Reichlin S. Somatostatin. N Engl J Med 1983; 309: 1495-501.
14. Cenni R, Lee SS. Hagengue A, Koshy A, Girod C, Lebrec D. Circulatory effects of somatostatin analogue in two conscious rat models of portal hypertension. Gastroenterology 1988; 94: 703-8.
15. Albillos A, Colombata LA, Lee FY, Groszmann RJ. Octreotide ameliorates vasodilation and sodium retention in portal hypertensive rats. Gastroenterology 1993; 104: 575-9.
16. Wang SS, Lee FY, Wu SL, et al. Effects of long-term administration of octreotide on sodium retention and atrial natriuretic peptide in carbon tetrachloride-induced cirrhotic rats. J Hepatol 1997; 26: 1128-34.
17. Lin HC, Yang MCM, Hou MC, et al. Effects of long-term administration of octreotide in portal vein-stenosed rats. Hepatology 1996; 23: 537-43.
18. Chu CJ, Lee FY, Wang SS, et al. Hyperdynamic circulation of cirrhotic rats with ascites: role of endotoxin, tumour necrosis factor-α and nitric oxide. Clin Sci 1997; 93: 219-25.
19. Lee FY, Wang SS, Yang MC, et al. Role of endotoxaemia in hyperdynamic circulation in rats with extrahepatic or intrahepatic portal hypertension. J Gastroenterol Hepatol 1996; 11: 152-8.
20. Albillos A, Colombato LA, Groszmann RJ. Vasodilatation and sodium retention in prehepatic portal hypertension. Gastroenterology 1992; 102: 931-5.
21. Albillos A, Colombato LA, Enriquez R, Cheng O, Sikuler E, Groszmann RJ. Sequence of morphological and haemodynamic changes of gastric microvessels in portal hypertension. Gastroenterology 1992; 102: 2066-70.
22. Colombato LA, Albillos A, Groszmann RJ. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal hypertensive rats. Hepatology 1992; 15: 323-8.
23. Benoit JN, Womack RA, Korthuis RJ, Wilborn WH, Granger DN. Chronic portal hypertension: effects on gastrointestinal flow distribution. Am J Physiol 1986; 250: G535-9.
24. Panés J, Casadevall M, Fernández M, et al. Gastric microcirculatory changes of portal-hypertensive rats can be attenuated by long-term oestrogen-progestagen treatment. Hepatology 1994; 20: 1261-70.
25. Yamada T, Chiba T. In: Schultz SG, Makhlouf GM, eds. Handbook of physiology. Section 6: The gastrointestinal system. Vol. 2. Neural and endocrine biology. Somatostatin. Baltimore: Waverty Press, 1989: 431-55.
26. Bendtsen F, Schifter S, Henriksen JH. Increased circulating calcitonin gene-related peptide (CGRP) in cirrhosis. J Hepatol 1991; 12: 118-23.
27. Fernández-Rodriguez CM, Prieto J, Quiroga J, et al. Plasma levels of substance P in liver cirrhosis: relationship to the activation of vasopressor systems and urinary sodium excretion. Hepatology 1995; 21: 35-40.
28. Pizcueta MP, Casamitjana R, Bosch J, Rodés J. Decreased systemic vascular sensitivity to norepinephrine in portal hypertensive rats: roles of hyperglucagonism. Am J Physiol 1990; 258: G191-5.
29. Mesh CL, Joh T, Korthuis RJ, Granger DN, Benoit JN. Intestinal vascular sensitivity to vasopressin in portal hypertensive rats. Gastroenterology 1991; 100: 916-21.
30. Nguyen LS, Villablanca AC, Rutledge JC. Substance P increases microvascular permeability via nitric oxide-mediated convective pathways. Am J Physiol 1995; 268: R1060-8.
31. Gray DW, Marshall I. Human α-calcitonin gene-related peptide stimulates adenylate cyclase and guanylate cyclase and relaxes rat thoracic aorta by releasing nitric oxide. Br J Pharmacol 1992; 107: 691-6.
32. Schini-Kerth VB, Fisslthaler B, Busse R. CGRP enhances induction of NO synthase in vascular smooth muscle cells via a cAMP-dependent mechanism. Am J Physiol 1994; 267: H2483-90.
33. Pizcueta P, Piqué JM, Fernández M, et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992; 103: 1909-15.
34. ω-nitro-L-arginine administration corrects peripheral vasodilation and systemic capillary hypotension and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology 1993; 17: 84-90.
35. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986; 250: H1145-9.
36. Buga GM, Gold GM, Fukuto JM, Ignarro LJ. Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension 1991; 17: 187-93.
37. Karalis K, Mastorakos G, Chrousos GP, Tolis G. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 1994; 93: 2000-6.
38. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumour necrosis factor α: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995; 108: 761-7.
39. Lopez-Talavera JC, Cadelina G, Merrill WW, Groszmann RJ. Role of tumour necrosis factor-alpha in the circulatory abnormalities of cirrhotic rats. Hepatology 1995; 22 (Suppl.): 256A.
40. Lopez-Talavera JC, Cadelina G, Merrill WW, Groszmann RJ. Thalidomide inhibits tumour necrosis factor α, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal hypertensive rats. Hepatology 1996; 23: 1616-21.
41. Ziada AM, Hudlicka O, Tyler KR, Wright AJ. The effect of long-term vasodilatation on capillary growth and performance in rabbit heart and skeletal muscle. Cardiovasc Res 1984; 18: 724-32.
42. Clark ER, Clark EL. Microscopic observations on the growth of blood capillaries in the living mammal. Am J Anat 1939; 64: 251-99.
43. Ziche M, Morbidelli L, Masini E, Granger H, Geppetti P, Ledda F. Nitric oxide promotes DNA synthesis and cyclic GMP formation in endothelial cells from postcapillary venules. Biochem Biophys Res Commun 1993; 192: 1198-203.
44. Leibovich SJ, Polverini PJ, Fong TW, Harlow LA, Koch AE. Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism. Proc Nad Acad Sci USA 1994; 91: 4190-4.
45. Ziche M, Morbidelli L, Masini E, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994; 94: 2036-44.
46. Woltering EA, Barrie R, O'Dorisio TM, et al. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 1991; 50: 245-51.
47. Barrie R, Woltering EA, Hajarizadeh H, et al. Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res 1993; 55: 446-50.
48. Reidy MA, Chopek M, Chao S, McDonald T, Schwartz SM. Injury induces increase of von Willebrand factor in rat endothelial cells. Am J Pathol 1989; 134: 857-64.
49. Duijvestijn AM, van Goor H, Klatter F, Majoor GD, van Bussel E, van Breda Vriesman PJC. Antibodies defining rat endothelial cells: RECA-I, a pan-endothelial cell-specific monoclonal antibody. Lab Invest 1992; 66: 459-66.